Mechanistic interactions between curcumin and statins: pharmacological convergence and therapeutic implications.

Cardiovascular and neurodegenerative disorders remain major contributors to global morbidity and mortality, underpinned by overlapping pathogenic processes including chronic inflammation, oxidative stress, endothelial dysfunction, and mitochondrial impairment. Therapeutic strategies capable of simultaneously modulating these interconnected pathways are increasingly recognized as essential for improving clinical outcomes. Curcumin (CUR), a pleiotropic polyphenolic compound derived from Curcuma longa, and statins, widely prescribed lipid-lowering agents, exhibit a broad spectrum of anti-inflammatory, antioxidant, and cytoprotective effects that extend beyond their canonical pharmacological actions. This review critically examines the molecular and pharmacological synergy between CUR and statins, with particular emphasis on their coordinated regulation of key signaling cascades, including NF-κB, iNOS, MAPK, and Nrf2-mediated antioxidant responses. Evidence from in vitro, in vivo, and emerging clinical studies indicates that CUR-statin co-administration may elicit additive or synergistic protective effects across diverse pathological contexts, such as atherosclerosis, myocardial ischemia-reperfusion injury, Alzheimer's disease, Parkinson's disease, and spinal cord injury, Myopathy, wound healing, and anti-cancer effects. Unfortunately, the majority of available experiments are preclinical and fewer clinical studies have been performed until now. At the cellular and tissue levels, this combinatorial approach appears to restore vascular homeostasis, preserve mitochondrial function, enhance neuronal survival, and suppress sustained inflammatory signaling. Collectively, the available data underscore a compelling pharmacological rationale for CUR-statin combination therapy as a multitarget intervention for complex cardiometabolic, neurodegenerative diseases, and a wide variety of disorders. Future investigations should focus on optimizing dosing regimens, improving CUR bioavailability, elucidating pharmacokinetic-pharmacodynamic interactions, and validating therapeutic efficacy through well-designed clinical trials.